Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This editorial discusses the terminology and distinctions between Low-Level Light/Laser Therapy and Photobiomodulation Therapy but reports no new clinical findings.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

In this research, authors found that skin-resident ILCs regulate sebaceous gland function and microbial balance, emphasizing an immune-epithelia system that supports host-microbe symbiosis.

This article discusses the SLICC's revision and validation of the ACR SLE classification criteria to enhance clinical relevance and integrate recent immunological insights, but does not report new clinical results.

This study found that LC-MS/MS assays provided more reliable and precise steroid measurements in human serum compared to traditional immunoassays, particularly at lower concentrations.

This study found that a high dose of LustrivaTM, containing biotin and silicon, significantly increased hair thickness and reduced facial wrinkle depth in women with thinning hair compared to a placebo, without any reported adverse events.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

Low level laser therapy may help with hair loss.

This study found that the transcription factor HB24 plays a critical role in root hair elongation in Arabidopsis thaliana by promoting the conversion of indole-3-butyric acid to indole-3-acetic acid through regulation of IBR1 expression.

This review summarizes various indices used to assess disease activity and damage in systemic lupus erythematosus, highlighting challenges in universal consensus and their practical applications in research and clinical settings.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

In this case study, DDS treatment for LABD was complicated by hemolytic anemia and alopecia, suggesting the need for careful monitoring of these potential side effects.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This study found that stilbamidine and hydroxystilbamidine can inhibit the release of specific enzymes from lysosomes and mitochondria in rabbit liver at certain concentrations, with effects similar to cortisol and chloroquine.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

This study highlights that hypoalbuminemia, often found in critically ill or elderly hospitalized patients, may increase morbidity, mortality, and hospitalization duration, suggesting specific conditions where oral or parenteral albumin supplementation should be considered.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this study, researchers found that the cell surface protein Lrig1 plays a crucial role in regulating the suppressive function of regulatory T cells, suggesting it as a potential target for treating autoimmune diseases, as evidenced by experiments in mouse models.

This study found that the Brigham Eyelash Tool for Alopecia (BELA) is a reliable measure for assessing eyelash loss in alopecia areata patients, demonstrating high inter- and intrarater reliability.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study concluded that removing alopecia and mucous membrane components from the CLASI-A score limits the ability to capture crucial clinical information about cutaneous lupus erythematosus activity, recommending their retention.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

This abstract discusses Lichen Sclerosus, a chronic skin condition affecting the genitals, highlighting its symptoms, complications, and impact on quality of life, but reports no new clinical findings.

This review discusses low level laser therapy for hair loss but reports no new research findings; it serves as an introduction to understanding existing knowledge before upcoming evaluations of recent studies.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study developed and validated a label-free assay using LC-MS to screen for S5αR inhibitors, identifying Thai herbal extracts, Impatiens balsamina L. and Curcuma longa L., as promising sources.